YOLFTbeta
Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd

CU6 · AU · Healthcare / Biotechnology

1.82AUD-0.23 (-11.46%)

Price History

Full chart

Market Stats

Previous Close2.05
Open2.05
Day Range1.82 – 2.09
52-Week Range1.80 – 5.87
Volume6.61M
Market Cap783.47M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.29
Dividend Yield0.00%
Beta1.18
50-Day Avg2.35
200-Day Avg2.81

About

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Michelle Parker
  • Employees100
  • HeadquartersNational Innovation Centre, Sydney, NSW, Australia, 2015, Australia
  • Websitehttps://www.claritypharmaceuticals.com

Leadership

  • Dr. Alan John Taylor Ph.D.Executive Chairman
  • Ms. Michelle ParkerCEO, MD & Executive Director
  • Mr. David K. Green BEc., CAChief Financial Officer
  • Dr. Colin David Biggin Ph.D.Chief Operating Officer
  • Dr. Ellen van Dam Ph.D.Chief Scientific Officer
  • Ms. Lisa SadetskayaDirector of Corporate Communications.
  • Ms. Mary BennettHead of People & Culture
  • Mr. Shaemus GleasonExecutive Vice President of Operations
  • Dr. Othon GervasioChief Medical Officer
  • Ms. Eva LengyelovaExecutive Vice President of Clinical Development

Financials

Income Statement

Currency: AUD2018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue2.46M2.64M2.79M3.20M6.46M9.80M11.51M9.46M-
Growth (%)-+7.43%+5.50%+14.62%+102.06%+51.74%+17.41%-17.76%-
Cost of Revenue23.83K22.02K17.00K15.63K46.25K100.51K153.07K185.08K283.53K
Gross Profit2.44M2.62M2.77M3.18M6.41M9.70M11.51M9.46M-283.53K
Gross Margin99.03%99.17%99.39%99.51%99.28%98.97%100.00%100.00%-
Operating Expense6.64M9.03M12.62M16.69M23.46M45.86M56.31M78.56M118.62M
Operating Income-4.20M-6.41M-9.85M-13.51M-17.05M-36.16M-44.80M-69.09M-118.91M
Operating Margin-170.67%-242.45%-353.06%-422.65%-263.94%-369.00%-389.35%-730.16%-
EBITDA-1.72M-4.96M-9.42M-13.38M-30.15M-34.20M-44.65M-68.91M-118.62M
EBITDA Margin-69.70%-187.79%-337.91%-418.51%-466.79%-348.95%-388.02%-728.21%-
Net Income-1.72M-3.68M-6.95M-10.22M-23.75M-24.60M-42.32M-64.30M-107.14M
Net Income Margin-69.86%-139.37%-249.35%-319.77%-367.78%-251.03%-367.83%-679.45%-
R&D1.47M2.11M4.03M9.68M18.90M31.46M45.78M66.88M91.08M
R&D as % of Total Revenue59.55%79.87%144.44%302.69%292.61%320.99%397.88%706.76%-
Interest Expense00000----
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%----

Balance Sheet

Currency: AUD2018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets2.79M10.36M9.12M22.61M99.82M76.90M154.63M101.17M199.06M
Total Liabilities857.04K1.14M956.09K2.34M7.59M7.72M8.33M10.94M12.96M
Total Equity1.93M9.23M8.16M20.28M92.24M69.18M146.30M90.23M186.11M
Cash1.68M3.89M5.27M8.44M55.34M31.21M47.90M47.68M178.25M
Net Debt-1.68M-3.89M-5.27M-8.44M-55.34M-65.01M-47.90M-47.68M-178.25M

Cash Flow

Currency: AUD2018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-1.50M-3.71M-6.83M-7.68M-13.31M-27.50M-43.24M-54.77M-92.55M
Investing Cash Flow-5.38K-15.67K-14.50K-60.31K-26.71M3.15M-55.31M51.99M-84.92M
Financing Cash Flow12.50K5.93M8.22M10.91M86.93M231.58K115.21M2.21M192.96M
Capital Expenditure5.38K15.67K14.50K60.31K213.15K46.56K504.00K182.74K306.92K
Free Cash Flow-1.50M-3.72M-6.84M-7.74M-13.53M-27.55M-43.74M-54.95M-92.85M
FCF to OCF100.36%100.42%100.21%100.79%101.60%100.17%101.17%100.33%100.33%

Earnings

Report DateFeb 27, 2022Aug 23, 2022Feb 28, 2023Feb 28, 2025Aug 18, 2025
EPS Estimate0.000.00-0.03-0.060.08
EPS Actual-0.06-0.04-0.04-0.07-0.13
Surprise---33.33%-27.27%-264.56%
TimingAfter-hoursAfter-hours--Pre-market

Key Statistics & Ratios

Market Cap783.47M
Enterprise Value601.49M
Trailing P/E0.00
Forward P/E0.00
Price / Sales74.43
Price / Book4.19
EPS-0.29
Book Value0.499
Revenue (TTM)10.53M
Gross Profit (TTM)10.53M
EBITDA-108.10M
Profit Margin0.00%
Operating Margin-1095.64%
Return on Equity-77.55%
Return on Assets-45.12%
Shares Outstanding373.08M
Shares Float288.69M
Beta1.18
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%